A post-marketing observational, non-inferiority surveillance study assessing the rates of occurrence of acute myocardial infarction (AMI) in persons receiving HEPLISAV-B compared with Engerix-B
Latest Information Update: 05 May 2021
At a glance
- Drugs Adjuvanted Hepatitis-B vaccine (Recombinant)-Dynavax (Primary) ; Hepatitis B vaccine recombinant
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms HBV-25
- 05 May 2021 New trial record
- 27 Apr 2021 According to Dynavax Technologies media release , results presented at the National Foundation for Infectious Diseases (NFID) 2021 Annual Conference on Vaccinology Research (ACVR).
- 27 Apr 2021 Primary endpoint (the rate of AMI in the HEPLISAV-B group with the Engerix-B group) has been met according to Dynavax Technologies Media Release